Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius ...

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than ...

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy ...

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) shares jumped 22.12% in after-hours trading to $1.27 on Tuesday, following the company’s fiscal year 2025 business update and the commercial launch of its ...

Citius Pharmaceuticals, Inc. CTXR announced top-line data from the pivotal phase III study evaluating its novel IL-2R immunotherapy, I/ONTAK (E7777), for the treatment of patients with persistent or ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

CTXR is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of CTXR shares has decreased $0.01 since the market last closed. This is a 1.88% ...